type 1 diabetes glp-1 In patients with residual ß-cell function, treatment GLP-1s are no longer the

Patients should be counseled ahead of time that transient worsening of diabetic retinopathy or macular edema can happen whenever there is rapid glucose improvement, but that there are significant long-term benefits for diabetic retinopathy

The value proposition includes pharmaceutical-grade compounds, sterile preparation, and clinical support that independent research suppliers can't provide

Women with diabetes who used GLP-1 agonists saw an even greater risk reduction compared with those who used insulin or metformin, but there was no significant difference when comparing GLP-1 meds and SGLT2 inhibitors

These findings relate to clinical trials on the active ingredients under specific study conditions they are not guaranteed outcomes for any individual patient using compounded formulations

Maintain a balanced lifestyle with regular exercise, relaxation techniques, and hobbies